Discontinuing psychotropic drug treatment

Area of Science:

• Psychiatry and Clinical Pharmacology
• Neuroscience
• Pharmacology

Background:

• Treatment interruption with psychiatric medications can lead to significant withdrawal symptoms and illness relapses.
• Stopping medication is not equivalent to being untreated, impacting patient outcomes.
• Discontinuation effects can complicate the interpretation of treatment responses in clinical and research settings.

Purpose of the Study:

• To highlight the clinical significance of withdrawal reactions and relapses following the interruption of psychiatric medications.
• To emphasize the distinction between stopping treatment and being untreated.
• To underscore the impact of discontinuation on treatment response interpretation.

Main Methods:

• Review of clinical observations and evidence regarding medication discontinuation.
• Analysis of withdrawal reactions, relapses, and recurrence of illness after stopping various psychiatric drugs.
• Examination of the effects of abrupt versus gradual discontinuation.

Main Results:

• Interruption of benzodiazepines, antidepressants, antipsychotics, and lithium can cause immediate or delayed adverse effects.
• Abrupt discontinuation of lithium, antipsychotics, and antidepressants leads to earlier clinical worsening compared to gradual tapering.
• Treatment termination can induce discontinuation and carry-over effects, influencing outcome interpretation.

Conclusions:

• Discontinuing psychiatric medications requires careful consideration due to potential withdrawal and relapse risks.
• Gradual tapering is generally preferred over abrupt cessation to mitigate adverse events.
• Understanding discontinuation effects is vital for accurate clinical practice and research trial interpretation.